Zemplar

   
Google
 
Web NewDrugInformation.com

Zemplar


Drug - Zemplar
The trade name of the product as shown on the labeling.

Dosage - INJECTABLE; INJECTION
The product dosage form and route separated by a semi-colon.

Active Ingredient(s) - Paricalcitol
Multiple ingredients are in alphabetical order.

Strength - 0.005MG/ML
The potency of the active ingredient(s), Paricalcitol. May repeat for multiple part products.

Applicant - ABBOTT
The firm name holding legal responsibility for Zemplar. The firm name is condensed to a maximum twenty character unique string.

New Drug Application (NDA) Number - 020819
The FDA assigned number to Zemplar. Format is nnnnnn.

Product Number - 001
The FDA assigned number to identify Zemplar. Each strength is a separate product. May repeat for multiple part products. Format is nnn.

Therapeutic Equivalence (TE) Code -
The TE Code indicates the therapeutic equivalence rating of generic to innovator Rx products.

Approval Date - Apr 17, 1998
The date Zemplar was approved as stated in the FDA approval letter to the applicant. The format is Mmm dd, yyyy. Products approved prior to the January 1, 1982 contain the phrase: "Approved prior to Jan 1, 1982".

Reference Listed Drug (RLD) - Yes
The pioneer or innovator of Zemplar. The RLD identifies the product Abbreviated New Drug Applications (ANDA) use as a reference. Format is Yes or No.

Type - RX
The group or category of approved drugs Zemplar is in. Format is RX, OTC, DISCN.

Applicant Full Name - Abbott Laboratories
The full name of the firm holding legal responsibility for the new application of Zemplar.

Zemplar